Get started
Author

Peter Johannsen

Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia
2015 · Willemijn J. Jansen, Rik Ossenkoppele, et al. · JAMA · 1,609
Mutations in the endosomal ESCRTIII-complex subunit CHMP2B in frontotemporal dementia
2005 · Gaia Skibinski, Nicholas J Parkinson, et al. · Nature Genetics · 824
Moderate-to-High Intensity Physical Exercise in Patients with Alzheimer’s Disease: A Randomized Controlled Trial
2016 · Kristine Hoffmann, Nanna A. Sobol, et al. · Journal of Alzheimer s Disease · 354
PDF
Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum
2022 · Willemijn J. Jansen, Olin Janssen, et al. · JAMA Neurology · 290
PDF
FUS pathology defines the majority of tau- and TDP-43-negative frontotemporal lobar degeneration
2010 · Hazel Urwin, Keith A. Josephs, et al. · Acta Neuropathologica · 248
PDF
Positron emission tomography of cortical centers of tinnitus
1999 · Frank Mirz, Christian Brahe Pedersen, et al. · Hearing Research · 216
Cerebral Blood Flow Measurements by Magnetic Resonance Imaging Bolus Tracking: Comparison with [ 15 O]H 2 O Positron Emission Tomography in Humans
1998 · Leif Østergaard, Peter Johannsen, et al. · Journal of Cerebral Blood Flow & Metabolism · 215
Cerebral activation during bicycle movements in man
2000 · L.O.D. Christensen, P. Johannsen, et al. · Experimental Brain Research · 194
Disruption of endocytic trafficking in frontotemporal dementia with CHMP2B mutations
2010 · Hazel Urwin, Astrid Authier, et al. · Human Molecular Genetics · 189
Brain Energy Metabolism and Blood Flow Differences in Healthy Aging
2012 · Joel Aanerud, Per Borghammer, et al. · Journal of Cerebral Blood Flow & Metabolism · 177
evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer’s disease
2025 · Jeffrey L. Cummings, Alireza Atri, et al. · Alzheimer s Research & Therapy · 162
PDF
Corticobasal and ataxia syndromes widen the spectrum of C9ORF72 hexanucleotide expansion disease
2012 · SG Lindquist, M Duno, et al. · Clinical Genetics · 143
EFNS task force: the use of neuroimaging in the diagnosis of dementia
2012 · M. Filippi, F. Agosta, et al. · European Journal of Neurology · 142
PDF
Association of Cerebral Amyloid-β Aggregation With Cognitive Functioning in Persons Without Dementia
2017 · Willemijn J. Jansen, Rik Ossenkoppele, et al. · JAMA Psychiatry · 140
PDF
A Reassessment of the Neuropathology of Frontotemporal Dementia Linked to Chromosome 3
2007 · Ida Elisabeth Holm, Elisabet Englund, et al. · Journal of Neuropathology & Experimental Neurology · 137
PDF
Potential genetic modifiers of disease risk and age at onset in patients with frontotemporal lobar degeneration and GRN mutations: a genome-wide association study
2018 · Cyril Pottier, Xiaolai Zhou, et al. · The Lancet Neurology · 132
Effect of aerobic exercise on physical performance in patients with Alzheimer's disease
2016 · Nanna Aue Sobol, Kristine Hoffmann, et al. · Alzheimer s & Dementia · 114
Chromosome 3 linked frontotemporal dementia (FTD-3)
2002 · S. Gydesen, J.M. Brown, et al. · Neurology · 112
Frontotemporal Dementia Caused by CHMP2B Mutations
2011 · A. M. Isaacs, P. Johannsen, et al. · Current Alzheimer Research · 99
PDF
Cerebral Metabolic Response to Low Blood Flow: Possible Role of Cytochrome Oxidase Inhibition
2005 · Albert Gjedde, Peter Johannsen, et al. · Journal of Cerebral Blood Flow & Metabolism · 98
PDF
Frontotemporal dementia caused by CHMP2B mutation is characterised by neuronal lysosomal storage pathology
2015 · Emma L. Clayton, Sarah Mizielinska, et al. · Acta Neuropathologica · 96
PDF
Prevalence of the apolipoprotein E ε4 allele in amyloid β positive subjects across the spectrum of Alzheimer's disease
2018 · Niklas Mattsson, Colin Groot, et al. · Alzheimer s & Dementia · 88
Origin of Human Motor Readiness Field Linked to Left Middle Frontal Gyrus by MEG and PET
1998 · Jane R. Pedersen, Peter Johannsen, et al. · NeuroImage · 86
Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials
2026 · Jeffrey L Cummings, Alireza Atri, et al. · The Lancet · 85
Cortical Sites of Sustained and Divided Attention in Normal Elderly Humans
1997 · Peter Johannsen, Johannes Jakobsen, et al. · NeuroImage · 82
Works count: 173
Citation count: 7,475
H-index: 38
I10-index: 70
Year
Topic
Type